Article: Celgene Corporation Announces Fourth Quarter Results and Growing Sales of Thalomid(TM).

Article: Pharmaceutical company announces record $34M in Thalomid ...
Biotech Week;  February 26, 2003 ;     700+ words ... ... announced that Thalomid (thalidomide ... million for the fourth quarter ended December ... developments * Thalomid prescriptions for the fourth quarter of 2002 increased ... previous quarter. Thalomid prescriptions for ...

Article: Thalomid sales boost third quarter revenues.
Biotech Week;  November 27, 2002 ;     700+ words ... ... significantly increasing Thalomid sales, finalizing the design ... four pivotal programs for Thalomid and Revimid with the FDA ... additional milestones in the fourth quarter such as the publication of Thalomid and Revimid data in peer ...

Article: Celgene Corporation Reports Record Operating Performance in Third ...
PR Newswire;  October 23, 2003 ;     700+ words ... ... achievements, including: record THALOMID sales and the initiation of ... multiple myeloma. Additionally, THALOMID's potential in cancers and ... look forward to an eventful fourth quarter with meaningful milestones ... presentations and publications around THALOMID, REVIMID and ACTIMID at ...

Article: First clinical data on Thalomid reported.
Drug Week;  April 18, 2003 ;     700+ words ... ... pilot, open-label clinical trials of Thalomid (thalidomide) in complex regional pain ... pilot, open-label clinical trials of Thalomid monotherapy in patients with CRPS based ... resolution of CRPS symptoms while receiving Thalomid in a multiple myeloma clinical trial ...

Article: Celgene Clinical and Regulatory Update; THALOMID(R) ...
PR Newswire;  March 7, 2002 ;     700+ words ... ... intends to seek marketing approval for THALOMID(R) (thalidomide) in early stage ... filing, the eventual expansion of the THALOMID label to include early stage multiple ... objective to receive regulatory approval for THALOMID for both hematological and solid tumor ...

Article: CELGENE ADVANCING THALOMID IN METASTATIC COLORECTAL ...
BIOWORLD Today;  May 18, 2001 ;     700+ words ...Celgene Corp. plans to aim its Thalomid at metastatic colorectal cancer in a trial that will team thalidomide, as Thalomid is generically known, with a Camptosar ... latest step in a long journey for Thalomid, which began its therapeutic life ...

Article: FDA Accepts Celgene's sNDATo Broaden Thalomid's Label.
BIOWORLD Today;  February 24, 2004 ;     700+ words ... ... moved one step closer to expanding Thalomid's label. The Warren, N.J.-based ... is getting increased use off-label. Thalomid (thalidomide) generated about $224 ... assuming that there is an approval for Thalomid in multiple myeloma, it certainly gives ...